Ultomiris for Paroxysmal Nocturnal Hemoglobinuria

News
Article

Ultomiris

ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)

Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria

Dosage: intravenous infusion only

  • 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance

  • 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance

  • 100kg ≤  X – 3,000mg leading, 3,600 maintenance

Contraindications: patients with unresolved Neisseria Meningitidis infection.

 

​Click here for more prescribing information

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.